基于磷脂基紫杉醇纳米前药的抗肿瘤应用研究

姚秀敏; 郝登远; 裴晴; 谢志刚; 景遐斌

doi:10.11777/j.issn1000-3304.2022.22409

您当前的位置：

首页 >

文章列表页 >

基于磷脂基紫杉醇纳米前药的抗肿瘤应用研究

研究论文 | 更新时间：2024-01-18

- 基于磷脂基紫杉醇纳米前药的抗肿瘤应用研究
  增强出版
- Phospholipid-hitchhiked Paclitaxel Nanoprodrugs for Tumor Treatment
- 高分子学报 2023年54卷第5期页码：708-719
- 作者机构：
  
  1.中国科学院长春应用化学研究所高分子物理与化学国家重点实验室长春 130022
  2.中国科学技术大学应用化学工程学院合肥 230026
- 作者简介：
  
  E-mail: peiqing@ciac.ac.cn
  xiez@ciac.ac.cn
- 基金信息：
  
  国家自然科学基金(基金号 ┣52203199);51973214┫;吉林省自然科学基金(基金号 YDZJ202101ZYTS013)
- DOI：10.11777/j.issn1000-3304.2022.22409
  中图分类号：
- 纸质出版日期：2023-05-20，
  
  网络出版日期：2023-02-17，
  
  收稿日期：2022-11-28，
  
  录用日期：2023-01-10
扫描看全文
姚秀敏,郝登远,裴晴等.基于磷脂基紫杉醇纳米前药的抗肿瘤应用研究[J].高分子学报,2023,54(05):708-719.

Yao Xiu-min,Hao Deng-yuan,Pei Qing,et al.Phospholipid-hitchhiked Paclitaxel Nanoprodrugs for Tumor Treatment[J].ACTA POLYMERICA SINICA,2023,54(05):708-719.
姚秀敏,郝登远,裴晴等.基于磷脂基紫杉醇纳米前药的抗肿瘤应用研究[J].高分子学报,2023,54(05):708-719. DOI： 10.11777/j.issn1000-3304.2022.22409.

Yao Xiu-min,Hao Deng-yuan,Pei Qing,et al.Phospholipid-hitchhiked Paclitaxel Nanoprodrugs for Tumor Treatment[J].ACTA POLYMERICA SINICA,2023,54(05):708-719. DOI： 10.11777/j.issn1000-3304.2022.22409.

摘要

载体材料是影响药物体内递送效率和抗肿瘤活性的重要因素. 本文应用2种不同结构的磷脂材料，包括聚乙二醇修饰的磷脂酰乙醇胺DSPE-PEG和磷脂酰胆碱DPPC，作为载体包裹紫杉醇二聚体(PTX

-SS)，制备了紫杉醇纳米颗粒. 相比于DPPC，DSPE-PEG作为载体有利于得到均匀的纳米剂型. 同时测定了DSPE-PEG作为载体制备的PTX

-SS@DSPE-PEG NPs (DeP NPs)在稳定性、细胞毒性、体内分布和抗肿瘤疗效方面的表现. 该工作为研发疏水药物的磷脂型载体提供了一个重要的参考.

Abstract

Carriers play crucial roles in improving the drug delivery efficacy and antitumor activity. Here

two kinds of phospholipid-based carriers

including PEGylated phosphatidyl ethanolamine DSPE-PEG and phosphatidyl choline DPPC

were leveraged to encapsulate dimeric paclitaxel prodrugs to obtain the formulations. The impact of phospholipid-based carriers on the colloidal stability

cytotoxicity

bio-distribution and antitumor efficacy was systemically investigated. Compared with DPPC

DSPE-PEG could form uniform nanoformulations (DeP NPs). The average particle size and zeta-potential of DeP NPs were determined to be 201.1 nm and -13.8 mV

respectively

by dynamic light scattering (DLS). The transmission electron microscopy (TEM) images confirmed their well-defined nanostructures. DeP NPs could remain stable in solutions containing 5% glucose

10% FBS

and RPMI-1640 without serum. The hydrophobic interaction dominates the assembly of DSPE-PEG with PTX prodrug. Upon treated with 10 mmol/L H

DeP NPs exhibited the oxidative responsive PTX release. DeP NPs could effectively be internalized by tumor cells

and exhibited more potent cytotoxicity towards cancer cells compared with normal cells. Furthermore

DeP NPs possessed good accumulation of drug at tumor sites and desirable antitumor performance. Our work provides valuable insight into the construction of phospholipid-based carriers material to deliver hydrophobic drugs.

关键词

磷脂紫杉醇二聚体前药纳米药物化疗

Keywords

PhospholipidPaclitaxelDimeric prodrugNanodrugsChemotherapy

references

Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584. doi:10.1038/nrc2167http://dx.doi.org/10.1038/nrc2167

Jordan M. A.; Toso R. J.; Thrower D.; Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(20), 9552-9556. doi:10.1073/pnas.90.20.9552http://dx.doi.org/10.1073/pnas.90.20.9552

Chabner B. A.; Roberts, T. G.Jr. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005, 5(1), 65-72. doi:10.1038/nrc1529http://dx.doi.org/10.1038/nrc1529

韩子意, 白雪峰, 王钰璋, 陈其文, 张先正. 用于增强结肠癌化疗的肠道菌群葡萄糖醛酸酶响应甘草酸胶束. 高分子学报, 2022, 53(6), 626-635. doi:10.11777/j.issn1000-3304.2022.22021http://dx.doi.org/10.11777/j.issn1000-3304.2022.22021

van der Meel R.; Sulheim E.; Shi Y.; Kiessling F.; Mulder W. J. M.; Lammers T. Smart cancer nanomedicine. Nat. Nanotechnol., 2019, 14(11), 1007-1017. doi:10.1038/s41565-019-0567-yhttp://dx.doi.org/10.1038/s41565-019-0567-y

Lu S. J.; Xia R.; Wang J.; Pei Q.; Xie Z. G.; Jing X. B. Engineering paclitaxel prodrug nanoparticles via redox-activatable linkage and effective carriers for enhanced chemotherapy. ACS Appl. Mater. Interfaces, 2021, 13(39), 46291-46302. doi:10.1021/acsami.1c12353http://dx.doi.org/10.1021/acsami.1c12353

焦自学, 陈杰, 田华雨, 陈学思. 聚乙烯亚胺介导siRNA和顺铂协同抗肿瘤治疗. 高分子学报, 2015, (1), 127-132. doi:10.11777/j.issn1000-3304.2015.14259http://dx.doi.org/10.11777/j.issn1000-3304.2015.14259

Wang J.; Pei Q.; Xia R.; Liu S.; Hu X. L.; Xie Z. G.; Jing X. B. Comparison of redox responsiveness and antitumor capability of paclitaxel dimeric nanoparticles with different linkers. Chem. Mater., 2020, 32(24), 10719-10727. doi:10.1021/acs.chemmater.0c04080http://dx.doi.org/10.1021/acs.chemmater.0c04080

Lv S. X.; Sylvestre M.; Prossnitz A. N.; Yang L. F.; Pun S. H. Design of polymeric carriers for intracellular peptide delivery in oncology applications. Chem. Rev., 2021, 121(18), 11653-11698. doi:10.1021/acs.chemrev.0c00963http://dx.doi.org/10.1021/acs.chemrev.0c00963

Zhu L.; Dong D.; Yu Z. L.; Zhao Y. F.; Pang D. W.; Zhang Z. L. Folate-engineered microvesicles for enhanced target and synergistic therapy toward breast cancer. ACS Appl. Mater. Interfaces, 2017, 9(6), 5100-5108. doi:10.1021/acsami.6b14633http://dx.doi.org/10.1021/acsami.6b14633

Kenry, Yeo T.; She D. T.; Nai M. H.; Marcelo Valerio V. L.; Pan Y. T.; Middha E.; Lim C. T.; Liu B. Differential collective cell migratory behaviors modulated by phospholipid nanocarriers. ACS Nano, 2021, 15(11), 17412-17425. doi:10.1021/acsnano.1c03060http://dx.doi.org/10.1021/acsnano.1c03060

Luo H.; Sheng J. Y.; Shi L. L.; Yang X. Y.; Chen J. T.; Peng T. H.; Zhou Q. B.; Wan J. L.; Yang X. L. Non-covalent assembly of albumin nanoparticles by hydroxyl radical: a possible mechanism of the NAB technology and a one-step green method to produce protein nanocarriers. Chem. Eng. J., 2021, 404, 126362. doi:10.1016/j.cej.2020.126362http://dx.doi.org/10.1016/j.cej.2020.126362

Su J. J.; Sun Q. N.; Lin S.; Lu S.; Zhang Q.; Li Y. X.; Li B.; Sun Y.; Liu K.; Zhang H. J.; Wang F.; Li J. J.; Wei Y. Biosynthetic and unfolded protein nanocarriers for chemotherapeutic drugs in oral cancers: improved bioavailability and safety of chemotherapeutics. Adv. Funct. Mater., 2022, 32(45), 2204271. doi:10.1002/adfm.202204271http://dx.doi.org/10.1002/adfm.202204271

Huang X. G.; Blum N. T.; Lin J.; Shi J. J.; Zhang C.; Huang P. Chemotherapeutic drug—DNA hybrid nanostructures for anti-tumor therapy. Mater. Horiz., 2021, 8(1), 78-101. doi:10.1039/d0mh00715chttp://dx.doi.org/10.1039/d0mh00715c

Ma W. J.; Zhan Y. X.; Zhang Y. X.; Mao C. C.; Xie X. P.; Lin Y. F. The biological applications of DNA nanomaterials: current challenges and future directions. Signal Transduct. Target. Ther., 2021, 6(1), 351. doi:10.1038/s41392-021-00727-9http://dx.doi.org/10.1038/s41392-021-00727-9

Goldberg M. S. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer, 2019, 19(10), 587-602. doi:10.1038/s41568-019-0186-9http://dx.doi.org/10.1038/s41568-019-0186-9

Wang Y. Q.; Li S. M.; Wang X. H.; Chen Q.; He Z. G.; Luo C.; Sun J. Smart transformable nanomedicines for cancer therapy. Biomaterials, 2021, 271, 120737. doi:10.1016/j.biomaterials.2021.120737http://dx.doi.org/10.1016/j.biomaterials.2021.120737

Xie A.; Hanif S.; Ouyang J.; Tang Z. M.; Kong N.; Kim N. Y.; Qi B. W.; Patel D.; Shi B. Y.; Tao W. Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine, 2020, 56, 102821. doi:10.1016/j.ebiom.2020.102821http://dx.doi.org/10.1016/j.ebiom.2020.102821

Wang M. Y.; Zhang L.; Cai Y. F.; Yang Y.; Qiu L. P.; Shen Y. T.; Jin J.; Zhou J.; Chen J. H. Bioengineered human serum albumin fusion protein as target/enzyme/pH three-stage propulsive drug vehicle for tumor therapy. ACS Nano, 2020, 14(12), 17405-17418. doi:10.1021/acsnano.0c07610http://dx.doi.org/10.1021/acsnano.0c07610

Li G. T.; Sun B. J.; Li Y. Q.; Luo C.; He Z. G.; Sun J. Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery. Small, 2021, 17(52), e2101460. doi:10.1002/smll.202101460http://dx.doi.org/10.1002/smll.202101460

Albert A. Chemical aspects of selective toxicity. Nature, 1958, 182(4633), 421-422. doi:10.1038/182421a0http://dx.doi.org/10.1038/182421a0

Bildstein L.; Dubernet C.; Couvreur P. Prodrug-based intracellular delivery of anticancer agents. Adv. Drug Deliv. Rev., 2011, 63(1-2), 3-23. doi:10.1016/j.addr.2010.12.005http://dx.doi.org/10.1016/j.addr.2010.12.005

潘烁炯, 许华平‍. 活性氧响应含碲高分子. 高分子学报, 2021, 52(8), 857-866. doi:10.11777/j.issn1000-3304.2021.21058http://dx.doi.org/10.11777/j.issn1000-3304.2021.21058

Hao D. Y.; Meng Q.; Jiang B. W.; Lu S. J.; Xiang X. J.; Pei Q.; Yu H. J.; Jing X. B.; Xie Z. G. Hypoxia-activated PEGylated paclitaxel prodrug nanoparticles for potentiated chemotherapy. ACS Nano, 2022, 16(9), 14693-14702. doi:10.1021/acsnano.2c05341http://dx.doi.org/10.1021/acsnano.2c05341

Wang Q.; Wang C.; Li S. Y.; Xiong Y. X.; Wang H. M.; Li Z.; Wan J. L.; Yang X. L.; Li Z. F. Influence of linkers within stimuli-responsive prodrugs on cancer therapy: A case of five doxorubicin dimer-based nanoparticles. Chem. Mater., 2022, 34(5), 2085-2097. doi:10.1021/acs.chemmater.1c03346http://dx.doi.org/10.1021/acs.chemmater.1c03346

Ling X.; Tu J. S.; Wang J. Q.; Shajii A.; Kong N.; Feng C.; Zhang Y.; Yu M.; Xie T.; Bharwani Z.; Aljaeid B. M.; Shi B. Y.; Tao W.; Farokhzad O. C. Glutathione-responsive prodrug nanoparticles for effective drug delivery and cancer therapy. ACS Nano, 2019, 13(1), 357-370. doi:10.1021/acsnano.8b06400http://dx.doi.org/10.1021/acsnano.8b06400

Qu Y.; Chu B. Y.; Wei X. W.; Lei M. Y.; Hu D. R.; Zha R. Y.; Zhong L.; Wang M. Y.; Wang F. F.; Qian Z. Y. Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for "on-demand" drug delivery. J. Control. Release, 2019, 296, 93-106. doi:10.1016/j.jconrel.2019.01.016http://dx.doi.org/10.1016/j.jconrel.2019.01.016

Ding H. T.; Tan P.; Fu S. Q.; Tian X. H.; Zhang H.; Ma X. L.; Gu Z. W.; Luo K. Preparation and application of pH-responsive drug delivery systems. J. Control. Release, 2022, 348, 206-238. doi:10.1016/j.jconrel.2022.05.056http://dx.doi.org/10.1016/j.jconrel.2022.05.056

Li S. M.; Shan X. Z.; Wang Y. Q.; Chen Q.; Sun J.; He Z. G.; Sun B. J.; Luo C. Dimeric prodrug-based nanomedicines for cancer therapy. J. Control. Release, 2020, 326, 510-522. doi:10.1016/j.jconrel.2020.07.036http://dx.doi.org/10.1016/j.jconrel.2020.07.036

Xia R.; Pei Q.; Wang J.; Wang Z. F.; Hu X. L.; Xie Z. G. Redox responsive paclitaxel dimer for programmed drug release and selectively killing cancer cells. J. Colloid Interface Sci., 2020, 580, 785-793. doi:10.1016/j.jcis.2020.07.086http://dx.doi.org/10.1016/j.jcis.2020.07.086

Pei Q.; Lu S. J.; Zhou J. L.; Jiang B. W.; Li C. N.; Xie Z. G.; Jing X. B. Intracellular enzyme-responsive profluorophore and prodrug nanoparticles for tumor-specific imaging and precise chemotherapy. ACS Appl. Mater. Interfaces, 2021, 13(50), 59708-59719. doi:10.1021/acsami.1c19058http://dx.doi.org/10.1021/acsami.1c19058

Zhou S. Y.; Hu X. L.; Xia R.; Liu S.; Pei Q.; Chen G.; Xie Z. G.; Jing X. B. A paclitaxel prodrug activatable by irradiation in a hypoxic microenvironment. Angew. Chem. Int. Ed. Engl., 2020, 59(51), 23198-23205. doi:10.1002/anie.202008732http://dx.doi.org/10.1002/anie.202008732

Salmaso S.; Mastrotto F.; Roverso M.; Gandin V.; de Martin S.; Gabbia D.; de Franco M.; Vaccarin C.; Verona M.; Chilin A.; Caliceti P.; Bogialli S.; Marzaro G. Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment. J. Control. Release, 2021, 340, 318-330. doi:10.1016/j.jconrel.2021.11.006http://dx.doi.org/10.1016/j.jconrel.2021.11.006

Koudelka Š.; Turánek J. Liposomal paclitaxel formulations. J. Control. Release, 2012, 163(3), 322-334. doi:10.1016/j.jconrel.2012.09.006http://dx.doi.org/10.1016/j.jconrel.2012.09.006

Barenholz Y. Doxil®—The first FDA-approved nano-drug: Lessons learned. J. Control. Release, 2012, 160(2), 117-134. doi:10.1016/j.jconrel.2012.03.020http://dx.doi.org/10.1016/j.jconrel.2012.03.020

Lai F.; Caddeo C.; Manca M. L.; Manconi M.; Sinico C.; Fadda A. M. What's new in the field of phospholipid vesicular nanocarriers for skin drug delivery. Int. J. Pharm., 2020, 583, 119398. doi:10.1016/j.ijpharm.2020.119398http://dx.doi.org/10.1016/j.ijpharm.2020.119398

Jiang L.; Chen W. Z.; Zhou S. S.; Li C.; Zhang X. K.; Wu W.; Jiang X. Q. Dendritic phospholipid-based drug delivery systems. Biomater. Sci., 2018, 6(4), 774-778. doi:10.1039/c7bm01001jhttp://dx.doi.org/10.1039/c7bm01001j

Liu S.; Wang X.; Yu X. L.; Cheng Q.; Johnson L. T.; Chatterjee S.; Zhang D.; Lee S. M.; Sun Y. H.; Lin T. C.; Liu J. L.; Siegwart D. J. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes. J. Am. Chem. Soc., 2021, 143(50), 21321-21330. doi:10.1021/jacs.1c09822http://dx.doi.org/10.1021/jacs.1c09822

Ladd J.; Zhang Z.; Chen S. F.; Hower J. C.; Jiang S. Y. Zwitterionic polymers exhibiting high resistance to nonspecific protein adsorption from human serum and plasma. Biomacromolecules, 2008, 9(5), 1357-1361. doi:10.1021/bm701301shttp://dx.doi.org/10.1021/bm701301s

更多指标>

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

用于增强结肠癌化疗的肠道菌群葡萄糖醛酸酶响应甘草酸胶束

pH敏感两亲性嵌段共聚物胶束的制备及其负载紫杉醇体外药效的研究

负载紫杉醇的聚乳酸纳米纤维对宫颈癌的抑制作用

聚乙二醇-聚磷酸酯嵌段共聚物的合成与性质以及对紫杉醇增溶作用的研究